Journal Watch · Frontiers in Immunology · 2026

Macrophage NPM1 drives anti-tumor immunity via the STAT3-CCRL2 axis.

Overexpression of <i>Npm1</i> in mice suppressed tumor growth, reduced M2 TAMs polarization, and enhanced CD8<sup>+</sup> T cell-mediated anti-tumor immunity.<h4>Conclusion</h4>Our findings revealed that NPM1 protects against tumor progression by regulating TAMs polarization and T cell function via the STAT3-CCRL2 axis.

Hong L, Yang Y, Han Y et al.Frontiers in Immunology3 min readPharma relevance 30/100

DOI: 10.3389/fimmu.2026.1748791PMID: 42559137Study type: preclinical (animal / model) study

TL;DR

Overexpression of <i>Npm1</i> in mice suppressed tumor growth, reduced M2 TAMs polarization, and enhanced CD8<sup>+</sup> T cell-mediated anti-tumor immunity.<h4>Conclusion</h4>Our findings revealed that NPM1 protects against tumor progression by regulating TAMs polarization and T cell function via the STAT3-CCRL2 axis.

Key findings

  • Mechanistically, NPM1 bound to p-TAT3/STAT3 and promoted transcription of CCRL2, a key regulator of macrophage polarization.
  • Overexpression of <i>Npm1</i> in mice suppressed tumor growth, reduced M2 TAMs polarization, and enhanced CD8<sup>+</sup> T cell-mediated anti-tumor immunity.<h4>Conclusion</h4>Our findings revealed that NPM1 protects against tumor progression by regulating TAMs polarization and T cell function via the STAT3-CCRL2 axis.

What they did

Here, we examined the function of NPM1 in regulating anti-tumor immunity within the tumor microenvironment.<h4>Methods</h4>The proportion and functional changes of macrophages and T cells were detected by flow cytometry, the downstream regulatory genes of <i>NPM1</i> were detected by RNA-seq, the binding ability of NPM1 and STAT3 was analyzed by Chip and luciferase assay.<h4>Results</h4>NPM1 inhibition or genetic deficiency promoted tumor growth in MC38 colon cancer and LLC lung cancer mice models. <i>Npm1<sup>+/-</sup></i> mice exhibited enhanced infiltration and polarization of immunosuppressive M2-like tumor-associated macrophages (TAMs) and impaired CD8<sup>+</sup> T cell function.

Full abstract (original)

Background: <h4>Background</h4>Although nucleophosmin (NPM1) is a well-characterized oncogene in acute myeloid leukemia, much less is known about its role in solid tumor immunity.

What they did: Here, we examined the function of NPM1 in regulating anti-tumor immunity within the tumor microenvironment.<h4>Methods</h4>The proportion and functional changes of macrophages and T cells were detected by flow cytometry, the downstream regulatory genes of <i>NPM1</i> were detected by RNA-seq, the binding ability of NPM1 and STAT3 was analyzed by Chip and luciferase assay.<h4>Results</h4>NPM1 inhibition or genetic deficiency promoted tumor growth in MC38 colon cancer and LLC lung cancer mice models. <i>Npm1<sup>+/-</sup></i> mice exhibited enhanced infiltration and polarization of immunosuppressive M2-like tumor-associated macrophages (TAMs) and impaired CD8<sup>+</sup> T cell function.

Results & conclusions: Mechanistically, NPM1 bound to p-TAT3/STAT3 and promoted transcription of CCRL2, a key regulator of macrophage polarization. Overexpression of <i>Npm1</i> in mice suppressed tumor growth, reduced M2 TAMs polarization, and enhanced CD8<sup>+</sup> T cell-mediated anti-tumor immunity.<h4>Conclusion</h4>Our findings revealed that NPM1 protects against tumor progression by regulating TAMs polarization and T cell function via the STAT3-CCRL2 axis.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1748791 · PubMed 42559137.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

Overexpression of <i>Npm1</i> in mice suppressed tumor growth, reduced M2 TAMs polarization, and enhanced CD8<sup>+</sup> T cell-mediated anti-tumor immunity.<h4>Conclusion</h4>Our findings revealed that NPM1 protects against tumor progression by regulating TAMs polarization and T cell function via the STAT3-CCRL2 axis.

What type of study is this?

It is a preclinical (animal / model) study, published in Frontiers in Immunology in 2026. Here, we examined the function of NPM1 in regulating anti-tumor immunity within the tumor microenvironment.<h4>Methods</h4>The proportion and functional changes of macrophages and T cells were detected by flow cytometry, the downstream regulatory genes of <i>NPM1</i> were detected by RNA-seq, the binding ability of NPM1 and STAT3 was analyzed by Chip and luciferase assay.<h4>Results</h4>NPM1 inhibition or genetic deficiency promoted tumor growth in MC38 colon cancer and LLC lung cancer mice models.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1748791. PubMed ID: 42559137. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Hong L, Yang Y, Han Y et al.. Macrophage NPM1 drives anti-tumor immunity via the STAT3-CCRL2 axis.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1748791.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/macrophage-npm1-drives-anti-tumor-immunity-via-the-stat3-ccrl2-axis-748791/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides